about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesAnimal models for Ebola and Marburg virus infectionsVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesViral hemorrhagic fevers: advancing the level of treatmentCurrent ebola vaccinesMucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responsesEbola Vaccination: If Not Now, When?A Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary ReportSustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAbEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentDelayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesEbola haemorrhagic feverEbolavirus vaccines for humans and apesClinical development of Ebola vaccinesPre-symptomatic diagnosis and treatment of filovirus diseasesVaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsMutations Abrogating VP35 Interaction with Double-Stranded RNA Render Ebola Virus Avirulent in Guinea PigsEfficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machineryEbola and Marburg virus vaccines.Updates in diagnosis and management of Ebola hemorrhagic fever.Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in MiceCHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques.Transcriptomic analysis reveals a previously unknown role for CD8+ T-cells in rVSV-EBOV mediated protection.Possible leap ahead in filovirus therapeutics.Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization.Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus.Are we any closer to combating Ebola infections?Infection control during filoviral hemorrhagic Fever outbreaks.Reversion of advanced Ebola virus disease in nonhuman primates with ZMappMedical research: Ebola therapy protects severely ill monkeys.Ebola virus disease: an update for anesthesiologists and intensivists.Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick.EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain.
P2860
Q21090120-461A5FDB-C594-4F1D-B382-5E6A1FBD912AQ21131118-C01DED17-5FD8-48BA-BC10-037E40ED2326Q21131585-EF01B0F0-0823-44F4-A8A0-22922B368728Q21245298-D5DD949F-A644-4082-8F60-0A733D140AB3Q21534720-5620E1F1-C426-4271-B5E7-280CC051E5E5Q21562420-677E1FFE-07AF-4E34-A015-56842FCB4CCAQ22305299-84BA4B83-189A-48C4-B541-95B75836C0C8Q24289295-C19F3574-9C84-4719-A8A3-453A9507931BQ24594601-DFF90485-AC0D-4E4F-8F40-2532B9B84E8DQ24597625-EA417D3D-1890-433C-937A-701EE2C27F49Q24612811-B7E0EFA9-BDBB-4526-9311-7C2929F991D6Q24629338-81A33B89-D40C-4950-8D14-6ACA29D5B485Q24631696-ABA23C34-A0EA-48DD-828E-ECD0A1AE68ECQ26775792-6F672275-FE7F-49A4-876C-850AAB2359DDQ26823831-F5B39A77-F3C7-4EDD-89D5-E6C8B139BFFFQ27485491-E26651F4-671A-4937-81D8-CC381E95A41EQ27658947-871B8C06-8380-4AE3-ADC6-35A1028D6CACQ28051937-AC9FEF07-4848-46B4-BB68-A41DC80CA6CDQ28475642-86660AA4-6308-4F0E-9D7A-346B1A747087Q30234637-F846E452-7FF0-4875-B1E9-200E6194293EQ30238537-4FE63417-5F7D-418A-8297-5C1C43D4E20DQ30375073-ABAEC15F-9120-4789-B199-50C700B42C47Q30383481-0EEA95AA-C147-4B2E-AD1D-35F039541CB3Q33404944-AFC6C015-8C16-425F-94A8-E99DEA737D61Q33681247-80E4406E-F5C8-4C77-9DE8-0E36AAC31ABEQ33701830-50A1C239-EFC6-4B22-A0D3-0987B9F7B83EQ33715773-1D7B8545-5BD4-490C-AA19-553FB7173293Q33721746-4B3DC4CB-F7AF-4FFB-920B-F19CCB82019AQ33768646-78FF6D51-B48E-48BC-B90F-5F5D46FBC738Q33818337-C1ECC0E3-415E-4A00-9433-8451A32EAE1AQ33826350-B85C9E2D-5A78-4D8B-9891-E5AC903C0334Q33981963-53881AF4-D2E4-4280-B87A-C9C49DA2F577Q34022601-03AD6E13-7813-4A1C-AF3C-D204F848EAD3Q34243483-1A1A4B7D-0330-4BA1-AECE-268924244E6FQ34426585-C13E9F7F-40E3-431F-8676-5BFA9328EC1DQ34435933-84F0B4C9-7997-4EC2-8883-F3D91350DAE3Q34446478-82D4EE47-A907-47CA-B272-8445FDFA661AQ34463780-3805D5D1-614C-4424-8B94-A0D49753A22CQ34465812-F574197E-D1DB-4A2A-B415-B171E2C30DF3Q34488551-4660C644-FEF8-407B-80D0-82D00FD08D4C
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Effective post-exposure treatment of Ebola infection
@ast
Effective post-exposure treatment of Ebola infection
@en
Effective post-exposure treatment of Ebola infection
@en-gb
Effective post-exposure treatment of Ebola infection
@nl
type
label
Effective post-exposure treatment of Ebola infection
@ast
Effective post-exposure treatment of Ebola infection
@en
Effective post-exposure treatment of Ebola infection
@en-gb
Effective post-exposure treatment of Ebola infection
@nl
altLabel
Effective Post-Exposure Treatment of Ebola Infection
@en
prefLabel
Effective post-exposure treatment of Ebola infection
@ast
Effective post-exposure treatment of Ebola infection
@en
Effective post-exposure treatment of Ebola infection
@en-gb
Effective post-exposure treatment of Ebola infection
@nl
P2093
P2860
P50
P3181
P1433
P1476
Effective post-exposure treatment of Ebola infection
@en
P2093
Elizabeth A Fritz
Joan B Geisbert
Lisa Fernando
Steven M Jones
P2860
P3181
P356
10.1371/JOURNAL.PPAT.0030002
P407
P50
P577
2007-01-01T00:00:00Z